Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post-menopausal women with breast cancer
1996

Effect of Anastrozole on Estrogen Levels in Post-Menopausal Women with Breast Cancer

Sample size: 12 publication Evidence: high

Author Information

Author(s): J Geisler, N King, M Dowsett, L Ottestad, S Lundgren, P Walton, PO Kormeset, PE L0nning

Primary Institution: Haukeland University Hospital

Hypothesis

Does anastrozole effectively inhibit aromatization and suppress plasma estrogen levels in post-menopausal women with breast cancer?

Conclusion

Anastrozole is highly effective in inhibiting aromatization and suppressing plasma estrogen levels in post-menopausal women with breast cancer.

Supporting Evidence

  • Anastrozole reduced aromatization from 2.25% to 0.074% and 0.043% for 1 mg and 10 mg doses respectively.
  • Plasma levels of oestrone, oestradiol, and oestrone sulphate were suppressed by over 86.5%, 83.5%, and 93.5% respectively.
  • All patients experienced a suppression of in vivo aromatization by over 93.7%.

Takeaway

Anastrozole helps lower estrogen levels in women with breast cancer, making it a good treatment option.

Methodology

Twelve post-menopausal women were randomized to receive either 1 mg or 10 mg of anastrozole daily for 28 days in a double-blinded crossover design.

Limitations

The study had a small sample size and included protocol deviators.

Participant Demographics

Mean age of participants was 65 years, and mean weight was 67 kg.

Statistical Information

P-Value

<0.005

Confidence Interval

95% confidence interval 1.73% - 2.92%

Statistical Significance

p<0.005

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication